Verve Therapeutics, Inc. financial data

Symbol
VERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Brookline Avenue, Suite 601, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K % +4.38%
Debt-to-equity 27.4 % +28.5%
Return On Equity -37.4 % +0.77%
Return On Assets -29.3 % +5.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84M shares +35.8%
Common Stock, Shares, Outstanding 83.8M shares +35.5%
Entity Public Float 940M USD -99.8%
Common Stock, Value, Issued 84K USD +35.5%
Weighted Average Number of Shares Outstanding, Basic 83.1M shares +34.5%
Weighted Average Number of Shares Outstanding, Diluted 83.1M shares +34.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 186M USD +21.9%
General and Administrative Expense 51.5M USD +20.9%
Operating Income (Loss) -222M USD -15.5%
Nonoperating Income (Expense) 25.3M USD +96.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -196M USD +6.44%
Income Tax Expense (Benefit) 381K USD
Net Income (Loss) Attributable to Parent -197M USD -9.84%
Earnings Per Share, Basic -2.87 USD/shares +8.31%
Earnings Per Share, Diluted -2.87 USD/shares +8.31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 144M USD +72.2%
Marketable Securities, Current 462M USD +8.76%
Cash, Cash Equivalents, and Short-term Investments 606M USD
Assets, Current 620M USD +19.8%
Property, Plant and Equipment, Net 21M USD -0.14%
Operating Lease, Right-of-Use Asset 83.5M USD -7.2%
Other Assets, Noncurrent 2.71M USD +282%
Assets 732M USD +15.4%
Accounts Payable, Current 3.05M USD -9.58%
Accrued Liabilities, Current 16.6M USD -12.9%
Liabilities, Current 31.3M USD -6.73%
Operating Lease, Liability, Noncurrent 63.5M USD -7.94%
Other Liabilities, Noncurrent 165K USD -36.5%
Liabilities 149M USD +19.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -500K USD -111%
Retained Earnings (Accumulated Deficit) -593M USD -49.7%
Stockholders' Equity Attributable to Parent 583M USD +14.4%
Liabilities and Equity 732M USD +15.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.1M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 22.7M USD +1016%
Net Cash Provided by (Used in) Investing Activities -41.6M USD -370%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 83.8M shares +35.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62M USD -95.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 149M USD +68.2%
Deferred Tax Assets, Valuation Allowance 172M USD +57%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 197M USD +45.1%
Operating Lease, Liability 73.7M USD -8.04%
Depreciation 5.96M USD +74.4%
Payments to Acquire Property, Plant, and Equipment 433K USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -197M USD -10.3%
Lessee, Operating Lease, Liability, to be Paid 103M USD -10.7%
Property, Plant and Equipment, Gross 33M USD +21.6%
Operating Lease, Liability, Current 10.2M USD -8.62%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2M USD +6.13%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +22.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.7M USD -16.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.5M USD +6.13%
Deferred Tax Assets, Operating Loss Carryforwards 51.3M USD +17.2%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 275K USD +419%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.9M USD +6.13%
Operating Lease, Payments 2.64M USD -16.1%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 275K USD +419%
Current Federal Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 37.4M USD +42.3%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%